Current management of functional dyspepsia: Impact of Rome III subdivision

Annals of Gastroenterology

Volumn 25, Issue 2, 2012, Pages 96-99

  Karamanolis, Georgios P ^a   Tack, Jan ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Functional dyspepsia; Rome III; Treatment

Indexed keywords

ACOTIAMIDE; ALEMCINAL; ASIMADOLINE; BUSPIRONE; CISAPRIDE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; FEDOTOZINE; ITOPRIDE; MOSAPRIDE; MOTILIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; NARONAPRIDE; NITRATE; PLACEBO; PROTON PUMP INHIBITOR; PRUCALOPRIDE; R 137696; RENZAPRIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 3 RECEPTOR; SILDENAFIL; SUMATRIPTAN; TANDOSPIRONE; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELUSETRAG; VENLAFAXINE;

CARDIOVASCULAR DISEASE; DISEASE CLASSIFICATION; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FEEDING BEHAVIOR; FOOD INTAKE; FUNCTIONAL DYSPEPSIA; HEART MUSCLE ISCHEMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERBAL MEDICINE; HUMAN; HYPNOSIS; IRRITABLE COLON; MEDICAL RESEARCH; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSCLE RELAXATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTION SIZE; POSTPRANDIAL STATE; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REASSURANCE; RECEPTOR BLOCKING; REVIEW; RISK REDUCTION; STOMACH ACID SECRETION; STOMACH MUSCLE; STOMACH PARESIS; SYMPTOM;

EID: 84859813382     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543-552.
2. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders Gastroenterology 2006;130:1466-1479.
3. Ang D, Talley NJ, Simren M, et al. Review article: endpoints used I functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-649.
4. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD002096.
5. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-1337.
6. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;18:CD001960.
7. Karamanolis G, Tack J. Promotility medications-now and in the future. Dig Dis 2006;24:297-307.
8. Thumshirn M, Fruehauf H, Stutz B, et al. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. Aliment Pharmacol Ther 2007;26:1399-1407.
9. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: a placebo-controlled, randomized study. Am J Gastroenterol 2008;103:1906-1919.
10. Chey WD, Howden CW, Tack J, et al. Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. Dig Dis Sci 2010;55:684-697.
11. Tack J, Janssen P, Bisschops R, et al. Influence of tegaserod on proximal gastric tone and on perception of gastric distention in functional dyspepsia. Neurogastroenterol Motil 2011;23:e32-e39.
12. Hongo M, Harasawa S, Mine T, et al. A large-scale, randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol 2012;27:62-68.
13. Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959-967.
14. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-696.
15. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-696.
16. Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998;26:312-320.
17. Chen SL, Ji JR, Xu P, et al. Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients. World J Gastroenterol 2010;16:613-617.
18. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832-840.
19. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008;57:740-746.
20. Sun J, Yuan YZ, Holtmann G. Itopride in the treatment of functional dyspepsia n Chinese patients: a prospective, multicentre, postmarketing observational study. Clin Drug Investig 2011;31:865-875.
21. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653-1661.
22. Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001;49:317-318.
23. Cuomo R, Vandaele P, Coulie B, et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 2006;101:804-811.
24. Camilleri M, Tack J. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin N Am 2010;39:481-493.
25. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebocontrolled, pilot trial of Z-338 in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-280.
26. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patient with functional dyspepsia-100 mg t.i.d. is an optimal dose. Neurogastroenterol Motil 2010;22:618-e173.
27. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012 (in press).
28. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide hydrochloride (Z-338) in patient with functional dyspepsia: results from an open label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 2011;84:261-268.
29. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255.
30. Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28:1326-1333.
31. Boeckxstaens G, Tytgat G, Wajs E, et al. The influence of the novel 5-HT1A agonist R-137696 on the proximal stomach functions in healthy volunteers. Neurogastroenterol Motil 2006;18:919-926.
32. Tack J, Van Elzen B, Tytgat G, et al. A placebo-contolled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009;21:619-623.
33. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone cicrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-2787.
34. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036-1042.
35. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptom, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160-165.
36. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746-752.
37. Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin reuptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003;17:603-608.
38. Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;CD002301.
39. Chiarioni G, Vantini I, De Iorio F, et al. Prokintic effect of gutoriented hypnosis on gastric emptying. Aliment Pharmacol Ther 2006;23:1241-1249.
40. Thompson Coon J, Ernst E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002;16:1689-1699.
41. Kusunoki H, Haruma K, Hata J, et al. Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern Med 2010;21:2195-2202.
42. Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997;41:664-668.
43. Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappaopioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008;27:1122-1131.